Compare VVPR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVPR | BDSX |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Precision Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 122.0M |
| IPO Year | 2016 | 2020 |
| Metric | VVPR | BDSX |
|---|---|---|
| Price | $2.15 | $17.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 1.2M | 153.6K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | N/A | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.62 | $0.25 |
| 52 Week High | $8.88 | $20.21 |
| Indicator | VVPR | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 62.47 |
| Support Level | $1.20 | $6.33 |
| Resistance Level | $2.90 | N/A |
| Average True Range (ATR) | 0.25 | 1.84 |
| MACD | -0.03 | 0.20 |
| Stochastic Oscillator | 30.19 | 65.98 |
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.